Vaginitis Therapeutics Market Size, Share, & Trends Analysis Report By Product (Anti-fungal, Hormone, Anti-bacterial), By Type (OTC, Prescription), By Region (APAC, MEA, North America), And Segment Forecasts, 2018 - 2025

Published: Oct, 2018 | Pages: 75 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global vaginitis therapeutics market size is expected to reach USD 4.21 billion by 2025, according to a new report by Grand View Research, Inc. It is estimated to expand at a CAGR of 8.4% during the forecast period. Supportive initiatives by government and non-government agencies to increase awareness level among women is driving the demand for vaginitis drugs. Increased consumption of alcohol is also estimated to fuel the adoption of these drugs. Around 5.3 million women in the U.S. are at risk related to health and general well-being.

Furthermore, rising R&D activities for vaginitis therapeutics is anticipated to accelerate the market growth. National Institute of Allergy and Infectious Diseases (NIAID)-funded research has discovered various important data about yeast generative behavior, which could result in new way of treatment for yeast infections. In addition, introduction of new drugs by key companies is expected to propel the market growth. For instance, in September 2017, Symbiomix Therapeutics received FDA approval for Solosec (secnidazole) for the treatment of bacterial vaginosis.

Further key findings from the study suggest:

• Anti-bacterial segment led the market in 2017 owing to the availability of a wide product range and higher number of cases of bacterial vaginosis disease

• Hormone is expected to witness lucrative growth with a CAGR of 9.1% over the forecast period due to the presence of pipeline products and rising adoption of products

• Prescription type held the largest market share in 2017, in terms of revenue. The segment was valued at USD 1.14 billion owing to the higher efficacy and safety of prescribed drugs and availability of a wide range of drugs for severe and recurring vaginitis

• Over the counter is expected to be the fastest-growing type in the coming years with a CAGR of 8.7% due to increasing number of FDA approvals for the treatment of mild vaginitis

• North America is estimated to be the largest regional market. It was the dominant region in 2017, in terms of revenue, owing to of high-quality healthcare services and increasing cases of vaginitis

• Asia Pacific is expected to be the fastest-growing region registering a lucrative CAGR over the forecast period. This growth is attributed to favorable government initiatives and rising disposable income along with the presence of a large target population base.

• Key players in the vaginitis therapeutics market are Pfizer, Inc.; Merck & Co.; Novartis AG; Bayer AG; Lupin Pharmaceuticals, Inc.; Symbiomix Therapeutics, Inc.; and Mission Pharmacal Company

• Most of these companies focus on strategic initiatives, such as collaborations, M&A, and product portfolio expansion. For instance, in October 2017, Lupin Pharmaceuticals acquired Symbiomix Therapeutics to expand its product portfolio.

 Table of Contents

Chapter 1 Research Methodology & Scope
                 1.1 Information Procurement
                     1.1.1 Purchased database:
                     1.1.2 GVR's internal database
                 1.2 Research Methodology
                 1.3 Geographic scope & assumptions
                 1.4 Region-wise market calculation
                     1.4.1 Region-wise market: Base estimates
                     1.4.2 Global market: CAGR calculation
                 1.5 Region-based segment share calculation
                 1.6 List of Secondary Sources
Chapter 2 Executive Summary
                 2.1 Market Snapshot
Chapter 3 Market Variables, Trends & Scope
                 3.1 Market Segmentation & Scope
                     3.1.1 Market driver analysis
                         3.1.1.1 Increasing prevalence of vaginitis
                         3.1.1.2 Rising R & D activities for vaginitis therapeutics
                         3.1.1.3 Changing lifestyle pattern of women
                     3.1.2 Market restraint analysis
                         3.1.2.1 Availability of alternative or natural remedies
                 3.2 Vaginitis Therapeutics - SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
                 3.3 Industry Analysis - Porter's
Chapter 4 Market Categorization 1: Product Estimates & Trend Analysis
                 4.1 Vaginitis Therapeutics Market: Product Movement Analysis
                 4.2 Anti-fungal
                     4.2.1 Anti-fungal market, 2014 - 2025 (USD Million)
                 4.3 Anti-bacterial
                     4.3.1 Anti-bacterial, 2014 - 2025 (USD Million)
                 4.4 Hormone
                     4.4.1 Hormone market, 2014 - 2025 (USD Million)
Chapter 5 Market Categorization 2: Type Estimates & Trend Analysis
                 5.1 Vaginitis Therapeutics Market: Type Movement Analysis
                 5.2 Over the counter (OTC)
                     5.2.1 Over the counter (OTC) market, 2014 - 2025 (USD Million)
                 5.3 Prescription (Rx)
                     5.3.1 Prescription (Rx), 2014 - 2025 (USD Million)
Chapter 6 Market Categorization 3: Regional Estimates & Trend Analysis, by Product & Type
                 6.1 Vaginitis Therapeutics Market Share by Region, 2017 & 2025
                 6.2 North America
                     6.2.1 North America vaginitis therapeutics market, 2014 - 2025 (USD Million)
                     6.2.2 U.S.
                         6.2.2.1 U.S vaginitis therapeutics market, 2014 - 2025 (USD Million)
                     6.2.3 Canada
                         6.2.3.1 Canada vaginitis therapeutics market, 2014 - 2025 (USD Million)
                 6.3 Europe
                     6.3.1 Europe vaginitis therapeutics market, 2014 - 2025 (USD Million)
                     6.3.2 U.K.
                         6.3.2.1 U.K. vaginitis therapeutics market, 2014 - 2025 (USD Million)
                     6.3.3 Germany
                         6.3.3.1 Germany vaginitis therapeutics market, 2014 - 2025 (USD Million)
                 6.4 Asia Pacific
                     6.4.1 Asia Pacific vaginitis therapeutics market, 2014 - 2025 (USD Million)
                     6.4.2 Japan
                         6.4.2.1 Japan vaginitis therapeutics market, 2014 - 2025 (USD Million)
                     6.4.3 China
                         6.4.3.1 China vaginitis therapeutics market, 2014 - 2025 (USD Million)
                 6.5 Latin America
                     6.5.1 Latin America vaginitis therapeutics market, 2014 - 2025 (USD Million)
                     6.5.2 Brazil
                         6.5.2.1 Brazil vaginitis therapeutics market, 2014 - 2025 (USD Million)
                     6.5.3 Mexico
                         6.5.3.1 Mexico vaginitis therapeutics market, 2014 - 2025 (USD Million)
                 6.6 MEA
                     6.6.1 MEA vaginitis therapeutics market, 2014 - 2025 (USD Million)
                     6.6.2 South Africa
                         6.6.2.1 South Africa vaginitis therapeutics market, 2014 - 2025 (USD Million)
Chapter 7 Competitive Landscape
                 7.1 Strategy framework
                 7.2 Market participation categorization
                 7.3 Company Profiles
                     7.3.1 Symbiomix Therapeutics LLC.
                         7.3.1.1 Company Overview
                         7.3.1.2 Financial Performance
                         7.3.1.3 Product Benchmarking
                         7.3.1.4 Strategic Initiatives
                     7.3.2 Merck & Co., Inc.
                         7.3.2.1 Company Overview
                         7.3.2.2 Financial Performance
                         7.3.2.3 Product Benchmarking
                         7.3.2.4 Strategic Initiatives
                     7.3.3 Pfizer Inc.
                         7.3.3.1 Company Overview
                         7.3.3.2 Financial Performance
                         7.3.3.3 Product Benchmarking
                         7.3.3.4 Strategic Initiatives
                     7.3.4 Novartis AG
                         7.3.4.1 Company Overview
                         7.3.4.2 Financial Performance
                         7.3.4.3 Product Benchmarking
                     7.3.5 Teva Pharmaceutical Industries Ltd.
                         7.3.5.1 Company Overview
                         7.3.5.2 Financial Performance
                         7.3.5.3 Product Benchmarking
                     7.3.6 Bayer AG
                         7.3.6.1 Company Overview
                         7.3.6.2 Financial Performance
                         7.3.6.3 Product Benchmarking
                         7.3.6.4 Strategic Initiatives
                     7.3.7 Janssen Pharmaceuticals Inc.
                         7.3.7.1 Company Overview
                         7.3.7.2 Financial Performance
                         7.3.7.3 Product Benchmarking
                     7.3.8 Lupin Pharmaceuticals Inc.
                         7.3.8.1 Company Overview
                         7.3.8.2 Financial Performance
                         7.3.8.3 Product Benchmarking
                         7.3.8.4 Strategic Initiatives
                     7.3.9 Lumavita AG.
                         7.3.9.1 Company Overview
                         7.3.9.2 Product Benchmarking
                     7.3.10 Mission Pharmacal Company.
                         7.3.10.1 Company Overview
                         7.3.10.2 Financial Performance
                         7.3.10.3 Product Benchmarking

List of Tables

TABLE 1 North America vaginitis therapeutics market, by product, 2014 - 2025 (USD Million)
TABLE 2 North America vaginitis therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 3 U.S. vaginitis therapeutics market, by product, 2014 - 2025 (USD Million)
TABLE 4 U.S. vaginitis therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 5 Canada vaginitis therapeutics market, by product, 2014 - 2025 (USD Million)
TABLE 6 Canada vaginitis therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 7 Europe vaginitis therapeutics market, by product, 2014 - 2025 (USD Million)
TABLE 8 Europe vaginitis therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 9 U.K. vaginitis therapeutics market, by product, 2014 - 2025 (USD Million)
TABLE 10 U.K. vaginitis therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 11 Germany vaginitis therapeutics market, by product, 2014 - 2025 (USD Million)
TABLE 12 Germany vaginitis therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 13 Asia Pacific vaginitis therapeutics market, by product, 2014 - 2025 (USD Million)
TABLE 14 Asia Pacific vaginitis therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 15 Japan vaginitis therapeutics market, by product, 2014 - 2025 (USD Million)
TABLE 16 Japan vaginitis therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 17 China vaginitis therapeutics market, by product, 2014 - 2025 (USD Million)
TABLE 18 China vaginitis therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 19 Latin America vaginitis therapeutics market, by product, 2014 - 2025 (USD Million)
TABLE 20 Latin America vaginitis therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 21 Brazil vaginitis therapeutics market, by product, 2014 - 2025 (USD Million)
TABLE 22 Brazil vaginitis therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 23 Mexico vaginitis therapeutics market, by product, 2014 - 2025 (USD Million)
TABLE 24 Mexico vaginitis therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 25 MEA vaginitis therapeutics market, by product, 2014 - 2025 (USD Million)
TABLE 26 MEA vaginitis therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 27 South Africa vaginitis therapeutics market, by product, 2014 - 2025 (USD Million)
TABLE 28 South Africa vaginitis therapeutics market, by type, 2014 - 2025 (USD Million)

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Value chain based sizing & forecasting
FIG. 4 QFD modeling for market share assessment
FIG. 5 Market summary, 2017
FIG. 6 Market trends & outlook
FIG. 7 Market segmentation & scope
FIG. 8 Market driver relevance analysis (Current & future impact)
FIG. 9 Market restrain relevance analysis (Current & future impact)
FIG. 10 SWOT analysis, by factor (political & legal, economic and technological)
FIG. 11 Porter's Five Forces Analysis
FIG. 12 Vaginitis therapeutics market type outlook key takeaways
FIG. 13 Vaginitis therapeutics market: Product movement analysis
FIG. 14 Global anti-fungal market, 2014 - 2025 (USD Million)
FIG. 15 Global anti-bacterial market, 2014 - 2025 (USD Million)
FIG. 16 Global hormone market, 2014 - 2025 (USD Million)
FIG. 17 Vaginitis therapeutics market type outlook key takeaways
FIG. 18 Vaginitis therapeutics market: Type movement analysis
FIG. 19 Global Over the counter (OTC) market, 2014 - 2025 (USD Million)
FIG. 20 Global prescription (Rx) market, 2014 - 2025 (USD Million)
FIG. 21 Regional market place: Key takeaways
FIG. 22 Regional outlook, 2017 & 2025
FIG. 23 North America vaginitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 24 U.S vaginitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 25 Canada vaginitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 26 Europe vaginitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 27 U.K. vaginitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 28 Germany vaginitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 29 Asia Pacific vaginitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 30 Japan vaginitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 31 China vaginitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 32 Latin America vaginitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 33 Brazil vaginitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 34 Mexico vaginitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 35 MEA vaginitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 36 South Africa vaginitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 37 Strategy framework
FIG. 38 Participant categorization